NCT06804161View on ClinicalTrials.gov

SGLT2 INHIBITION for CARDIOVASCULAR ENDPOINT REDUCTION in HYPERTENSION

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

3,000

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

May 30, 2032

Study Completion Date

May 30, 2032

Conditions
Atrial Hypertension
Interventions
DRUG

SGLT2

10 mg

DRUG

Placebo

1 tablet

All Listed Sponsors
lead

Prof. Dr. med. Ingo Eitel

OTHER